Avantor Inc. reported net sales of USD 1,663.6 million for the fourth quarter (Q4) of 2025, reflecting a 1.4 percent decrease compared to the same period in the prior year. Gross profit for Q4 2025 amounted to USD 523.9 million. Net income for the quarter was USD 52 million, while adjusted net income stood at USD 146 million. Adjusted operating income reached USD 510 million, with an adjusted operating income margin of 11.6 percent. For the full year (FY) 2025, net sales totaled USD 6,552.2 million. Gross profit was USD 2,139.4 million, and selling, general and administrative expenses were USD 1,595.5 million. The company recorded impairment charges of USD 785 million for the year. In the Bioscience Production segment, net sales for FY 2025 were USD 2,153 million, representing a 1.0 percent reported decrease. Adjusted operating income in this segment was USD 518 million, with an adjusted operating income margin of 24.1 percent. During the earnings release, Avantor highlighted the initiation of a business transformation plan, "Revival," aimed at driving top-line growth and strengthening the company. Management described 2026 as a year of transition and purposeful investment, emphasizing the company's commitment to sustainable shareholder value creation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avantor Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY85461) on February 11, 2026, and is solely responsible for the information contained therein.
Comments